Venture&Growth
Location
Munich, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Venture&Growth
Nalu Medical
Nalu Medical is a US medical device company that commercializes alternative proprietary neuromodulation systems. These systems treat chronic neuropathic pain in the back, legs, and other peripheral parts of the body, affecting 1.5 million patients. Nalu’s miniaturized implantable pulse generator
Venture&Growth
Affimed
Affimed (Nasdaq: AFMD) is a German therapeutics company committed to utilizing the untapped potential of the innate immune system to restore patients’ natural ability to fight cancer. Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing
Venture&Growth
Shoulder Innovations
Shoulder Innovations is a US-based medical device company that is commercializing a novel shoulder arthroplasty portfolio paired with an AI-enabled surgical planning software. The portfolio is anchored by Shoulder Innovations’ proprietary InSetTM glenoid fixing technology to solve the problem of
